Actionable news
0
All posts from Actionable news
Actionable news in LLY: ELI LILLY & CO.,

Eli Lilly And Company Lilly Corporate Center

The following excerpt is from the company's SEC filing.

Indianapolis, Indiana 46285

U.S.A.

+1.317.276.2000

www.lilly.com

For Release:

Immediately

Refer to:

Lauren Zierke; lauren_zierke@lilly.com; (317) 277-6524 (Media)

Philip Johnson; johnson_philip_l@lilly.com; (317) 655-6874 (Investors)

Lilly Reports Third-Quarter 2015 Results, Revises 2015 Financial Guidance

Revenue increased

2 percent

with the inclusion of Novartis Animal Health and higher volume for several products, including Cyramza and Trulicity; these contributions were partially offset by the unfavorable effect of forei gn exchange rates and the residual impact of the Cymbalta patent expiration.

Third-quarter 2015 earnings per share were

(reported), or

(non-GAAP).

Significant pipeline progress has continued with positive Jardiance cardiovascular outcomes data, two positive topline results for baricitinib and Breakthrough Therapy Designation for abemaciclib, as well as the acquisition of a promising Phase III intranasal glucagon and multiple oncology collaborations.

2015 EPS guidance has been revised to be in the range of $2.40 to $2.45 on a reported basis and $3.40 to $3.45 on a non-GAAP basis, reflecting solid underlying performance and net investment gains in the third quarter.

Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2015.

$ in millions, except per share data

Third Quarter

Change

Revenue – Reported

4,959.7

4,875.6

Net Income – Reported

EPS – Reported

Revenue – non-GAAP

5,151.0

Net Income – non-GAAP

EPS – non-GAAP

Certain financial information for 2015 and 2014 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were

prepared in accordance with generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the period. Non-GAAP measures exclude the items described in the reconciliation tables later in the release. Non-GAAP measures in 2014 include the results of Novartis Animal Health as if the acquisition and the financing for the acquisition had occurred as of January 1, 2014. Non-GAAP financial measures for all periods presented also exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties. The company’s 2015 financial guidance is also being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company’s business.

“We are pleased with our strong third-quarter results, which reflect the ongoing actions we are taking to grow revenue and increase productivity while we are replenishing and advancing our pipeline with an array of new, innovative therapies,” said John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer. “Despite headwinds from foreign exchange rates, we are benefiting from recent launches as well as our acquisition of Novartis Animal Health earlier this year.”

“This quarter, we had higher sales volume for several key products, including recently launched Cyramza and Trulicity. We also launched several new products in various global markets, including Synjardy in the U.S. for type 2 diabetes. Promising pipeline momentum continued with encouraging news for baricitinib and abemaciclib, while Jardiance reported positive cardiovascular outcomes. Finally, we continued to create new collaborations and pursue smaller-scale acquisitions to bolster our pipeline and our product portfolio.”

Looking forward, Lechleiter noted that Lilly could have a regulatory submission and/or decision for multiple potential new medicines in the next 18 months -- reinforcing the company’s confidence in its innovation-based strategy and in its ability to grow revenue and expand margins over the balance of this decade.

Key Events Over the Last Three Months

Commercial

The company launched Basaglar

, a basal insulin product, in Japan, the UK, Germany and other European markets. Basaglar is part of the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.

The company launched Trulicity

in Japan as a treatment for type 2 diabetes.

Regulatory

The U.S. Food and Drug Administration (FDA) approved Synjardy

(empagliflozin and metformin hydrochloride) tablets and the product was launched in the U.S. for the treatment of adults with type 2 diabetes. Synjardy is part of the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.

The FDA granted Breakthrough Therapy Designation to abemaciclib for patients with refractory hormone-receptor-positive advanced or metastatic breast cancer. Breakthrough Therapy Designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

Clinical

The company and Boehringer Ingelheim announced positive results from a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance

in adults with type 2 diabetes at high risk for CV events. Jardiance is the only diabetes medicine to have demonstrated a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcomes trial.

The company will terminate the Phase III trials of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease due to insufficient efficacy.

The company and Incyte Corporation announced positive top-line results for baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.

The third Phase III study evaluating safety and efficacy of baricitinib met its primary

objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response rate after 24 weeks of treatment. Additionally, baricitinib was superior to methotrexate based on ACR20 response.

The fourth Phase III study of baricitinib met its primary objective of demonstrating superiority compared to placebo after 12 weeks of treatment based on ACR20 response rate. Baricitinib was also superior to adalimumab in improving signs and symptoms of rheumatoid arthritis as measured by ACR20 response and improvement in the DAS28-hsCRP score after 12 weeks of treatment.

Business Development/Other

The company announced external innovation agreements with:

AstraZeneca to expand their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors. The company and AstraZeneca will evaluate the safety and efficacy of a range of additional combinations across the companies’ complementary portfolios.

ImaginAb Inc. to conduct preclinical research studying potential novel T-cell-based immuno-oncology therapies.

Innovent Biologics, Inc. to expand their collaboration to support the development and potential commercialization of up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, both inside and outside of China.

The company acquired worldwide rights from Locemia Solutions to a Phase III intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin.

Bristol-Myers Squibb transferred its Erbitux

commercialization rights to Lilly in North America.

The company entered into a settlement agreement to resolve patent litigation with Sanofi regarding the company’s insulin glargine product, Basaglar. As a part of the agreement, Lilly and its alliance partner, Boehringer Ingelheim, will have the ability to launch Basaglar in the U.S. on December 15, 2016. Under the terms of the agreement, Sanofi granted Lilly a royalty-

bearing license so Lilly can manufacture and sell Basaglar in the Kwikpen

device globally.

The U.S. District Court for the Southern District of Indiana ruled that the Alimta

vitamin regimen patent would be infringed by the generic challengers’ proposed products. The patent provides intellectual property protection for Alimta until May 2022.

The Japan Patent Office issued a notice of closure in the trial regarding the validity of Lilly’s vitamin regimen patent for Alimta. We expect a written decision upholding the patent validity in the coming weeks. This is the first of two decisions pending. If the patents are ultimately upheld through all challenges and appeals, they would provide intellectual property protection for Alimta in Japan until June 2021.

The company plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York, New York. Upon completion in 2016, this space will include a translational immuno-oncology hub and a Lilly “portal,” which will provide local academic scientists with opportunities for collaborative access to cutting-edge drug discovery capabilities.

Third-Quarter Reported Results

In the third quarter of 2015, worldwide revenue was

$4.960 billion

, an increase of

percent compared with the third quarter of 2014. The revenue growth included an increase of

percent due to increased volume, largely offset by decreases of

percent due to the unfavorable impact of foreign exchange rates and

percent due to lower prices. The

12 percent

increase in volume was primarily due to the inclusion of revenue from Novartis Animal Health and increased volume for several products, including the U.S. Evista

authorized generic, Cyramza

and Trulicity. These worldwide volume increases were partially offset by lower demand for Cymbalta

due to the U.S. patent expiration in December 2013. Revenue in the U.S. increased

percent to

$2.538 billion

, due primarily to higher volume, partially offset by lower prices. The U.S. price decrease was driven by a lower price for the Evista authorized generic, which more than offset higher prices for other products. Revenue outside the U.S. decreased

$2.422 billion

, driven by the unfavorable impact of foreign exchange

rates, partially offset by the inclusion of revenue from Novartis Animal Health and increased volumes for the majority of pharmaceutical products.

Gross margin increased

percent to

$3.723 billion

in the third quarter of 2015, as the favorable impact of foreign exchange rates on cost of sales, including the impact on international inventories sold, the inclusion of Novartis Animal Health and increased contribution from recently launched products were largely offset by the unfavorable impact of foreign exchange rates on revenue. Gross margin as a percent of revenue was

75.1 percent

percentage points compared with the third quarter of 2014. The increase in gross margin percent was primarily due to the favorable impact of foreign exchange rates on international inventories sold, partially offset by the inclusion of Novartis Animal...


More